Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Regenerating Muscle in Duchenne Muscular Dystrophy

April 15, 2014 11:04 am | News | Comments

A team of scientists has published details of how a class of drugs called “HDACis” drive muscle-cell regeneration in the early stages of dystrophic muscles, but fail to work in late stages. Read more...              

TOPICS:

Potential New Way to Fight Malaria Drug Resistance

April 15, 2014 10:56 am | News | Comments

An anti-malarial treatment that lost its status as the leading weapon against the deadly disease could be given a new lease of life, with new research indicating it simply needs to be administered differently. Read more...        

TOPICS:

Mylan, Prosonix Enter Global Deal on Generic Respiratory Meds

April 15, 2014 10:44 am | News | Comments

Prosonix announced that it has entered into a global licensing agreement with Mylan Inc. for its leading inhaled respiratory products, PSX1001 and PSX1050, being developed as generic versions to GlaxoSmithKline’s pressurized metered dose inhalers. Read more...

TOPICS:
Advertisement

FDA OKs Trials for Vivolux First-in-Class Cancer Drug

April 15, 2014 10:32 am | News | Comments

Vivolux AB announced that the FDA has granted clearance to proceed with VLX600 into clinical Phase 1/2 trials. The drug candidate kills sleeping cell populations in regions of solid tumors that are metabolically compromised due to poor vascularization. Read more...

TOPICS:

Actavis Agrees to Generess FE Patent Settlement

April 15, 2014 10:22 am | News | Comments

Actavis plc announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess FE. Read more...             

TOPICS:

Ex Vivo Data Supports Mast's Sickle Cell Treatment

April 14, 2014 2:19 pm | News | Comments

Mast Therapeutics Inc. announced that, in an ex vivo study, MST-188 reduced the mean erythrocyte sedimentation rate (ESR) by 50% relative to control in blood collected from individuals with sickle cell disease. Read more...         

TOPICS:

Lexicon’s Type 1 Diabetes Trial Gets Positive Results

April 14, 2014 1:53 pm | News | Comments

Lexicon Pharmaceuticals Inc. announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. Read more...

TOPICS:

J&J is First Collaborator in Scripps’ Drug Discovery Initiative

April 14, 2014 1:48 pm | News | Comments

The Scripps Research Institute (TSRI) announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. Read more...

TOPICS:
Advertisement

FDA Accepts BI, Lilly NDA for Type 2 Diabetes Combo Tablet

April 14, 2014 1:39 pm | News | Comments

Boehringer Ingelheim and Eli Lilly and Co. announced that the FDA accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes. Read more...

TOPICS:

Mouse Model Breakthrough for Alzheimer's Research

April 14, 2014 1:27 pm | News | Comments

In a new study, a group of researchers has reported the creation of two new mouse models of Alzheimer’s disease that may potentially revolutionize research into this disease. Read more...                  

TOPICS:

BMS Files NDA for HIV Combo Treatment

April 14, 2014 12:59 pm | News | Comments

Bristol-Myers Squibb announced the submission of a new drug application (NDA) to the FDA for a fixed-dose combination of atazanavir sulfate and cobicistat that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Read more...

TOPICS:

Ipsen's Dysport Helps Upper Limb Spasticity in Phase 3 Trial

April 14, 2014 11:04 am | News | Comments

Ipsen announced that a first set of results on Phase 3 clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity was presented on Saturday at the World Congress for NeuroRehabilitation in Istanbul. Read more...   

TOPICS:

Janssen Posts Final Data from Phase 2 COSMOS Study

April 14, 2014 10:44 am | News | Comments

Janssen announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93% of patients with the hepatitis C virus (HCV) and advanced liver fibrosis who were treated with simeprevir and Gilead's sofosbuvir achieved sustained virologic response 12 weeks after the end of treatment (SVR12). Read more...

TOPICS:

Astellas European Foundation Awards 2014 Urology Grant

April 14, 2014 10:23 am | News | Comments

The Astellas European Foundation is announced the recipient of the 2014 Functional Urology and Uro-Gynecology Grant as Dr. Marianne Gamper for a project to be undertaken jointly in Austria and Switzerland to quantify marker levels to identify the potential relationship between Overactive Bladder Syndrome and Bladder Pain Syndrome/Interstitial Cystitis. Read more...

TOPICS:

Abbvie’s Ribavirin Promising for Hep C Patients with Liver Cirrhosis

April 14, 2014 10:13 am | News | Comments

AbbVie announced results from the Phase 3 TURQUOISE-II, which evaluated the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's regimen with ribavirin (RBV) in adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection with compensated liver cirrhosis. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading